[go: up one dir, main page]

WO2024191115A1 - Composition pour la prévention, l'amélioration ou le traitement de maladies gastro-intestinales, comprenant un extrait de cucumis melo l. en tant que principe actif - Google Patents

Composition pour la prévention, l'amélioration ou le traitement de maladies gastro-intestinales, comprenant un extrait de cucumis melo l. en tant que principe actif Download PDF

Info

Publication number
WO2024191115A1
WO2024191115A1 PCT/KR2024/002956 KR2024002956W WO2024191115A1 WO 2024191115 A1 WO2024191115 A1 WO 2024191115A1 KR 2024002956 W KR2024002956 W KR 2024002956W WO 2024191115 A1 WO2024191115 A1 WO 2024191115A1
Authority
WO
WIPO (PCT)
Prior art keywords
gastric
extract
composition
preventing
fruit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/KR2024/002956
Other languages
English (en)
Korean (ko)
Inventor
김동선
이윤미
손은정
조규형
김소연
육흥주
성윤영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020240029392A external-priority patent/KR20240138984A/ko
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2024191115A1 publication Critical patent/WO2024191115A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to a composition for preventing, improving or treating gastrointestinal diseases containing an extract of Cucumis melo L. as an effective ingredient.
  • the present invention is a result of the project 'Establishment of Safety and Efficacy of Herbal Medicine Prescriptions in Oriental Medicine Institutions (Development of Herbal Medicine Formulation Technology for On-Site Demand with Increased Ease of Taking)' (Project No.: 1711195899, KSN1823312) supported by the research operation expenses of the Korea Institute of Oriental Medicine under (or affiliated with) the Ministry of Science and ICT, and the project 'Basic Research for Interpreting the Pathological Characteristics of Gallbladder Syndrome and Optimizing Clinical Application' (Project No.: 1711187922, 2022M3A9E4084134 (NSN2212190)) supported by the Biomedical Technology Development Project of the National Research Foundation of Korea under (or affiliated with) the Ministry of Science and ICT.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • COX cyclooxygenase
  • COX is an enzyme that converts arachidonic acid, the first step in the PG (prostaglandin) biosynthesis process, into PG and thromboxane.
  • PGs mainly produced in the stomach and duodenum are PG E2, I2, and F2 ⁇ , which promote the production of mucus and bicarbonate, regulate blood circulation in the mucosa, protect the mucosal damage, preserve the gastric mucosal barrier, and promote cell proliferation.
  • Most NSAIDs inhibit PG production by inhibiting COX, the rate-limiting enzyme for PG production, and this effect appears mainly through the systemic effect rather than the local effect of NSAIDs.
  • two isoforms of COX are known, COX-1 and COX-2.
  • COX-1 is a constitutive enzyme that is expressed in most tissues of the human body and acts as a "house-keeping gene" to protect the gastrointestinal mucosa, regulate blood flow to the kidneys, and maintain platelet function.
  • COX-2 is an induced enzyme, which is not expressed in most tissues under normal conditions, but its expression increases when inflammation occurs in these tissues. According to the "COX-2 hypothesis,” the therapeutic effect of NSAIDs is mainly achieved by inhibition of COX-2, and inhibition of COX-1 is reported to cause side effects in the gastrointestinal tract.
  • Cucumis melo var. makuwa is a plant belonging to the cucurbit family and is known to have originated from the hot and dry regions of Central Asia. In Donguibogam, it is said that Cucumis melo var. makuwa has an expectorant effect and is also effective for wind phlegm, jaundice, dropsy, and diuresis. However, pharmacological research is still lacking.
  • the fruit body refers to the top of the melon ( Cucumis melo L.) of the gourd family or the unripe melon.
  • Cheomgwa is a character meaning the shape of cucumbers hanging from a vine. It has almost no smell, tastes very bitter, and is cold and poisonous in nature.
  • the fruit body is a medicine to induce vomiting when you have indigestion and chest tightness, and is a fever-clearing medicine that is effective for jaundice-type hepatitis, edema of the limbs, and sinusitis.
  • Korean Patent No. 1498363 discloses a composition for preventing or treating diabetes containing the extract of the plant seed as an active ingredient
  • Korean Patent Publication No. 2011-0060788 discloses a composition for preventing or treating brain diseases containing the extract of the plant as an active ingredient.
  • a composition for preventing, improving or treating gastrointestinal diseases containing the extract of the plant of the present invention as an active ingredient has not yet been disclosed.
  • the present invention was derived from the above needs, and the present invention provides a composition for preventing, improving or treating gastric diseases containing a citrus fruit extract as an effective ingredient, and the gastric lesion index due to gastric mucosal damage is significantly reduced by administration of the citrus fruit extract, and the histamine content, which causes a lot of acid secretion and mucosal damage in a state of gastric stimulation or inflammation, is reduced, and the gene expression amount of inflammatory cytokines in the gastric mucosa is reduced, and the gene expression amount of proteins showing an antioxidant effect in the gastric mucosa and proteins having a gastric protective function is increased.
  • the present invention was completed.
  • the present invention provides a health functional food composition for preventing or improving gastrointestinal diseases containing an extract of Cucumis melo as an effective ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating gastrointestinal diseases containing an extract of Cucumis melo as an effective ingredient.
  • the present invention provides a feed additive for preventing or improving gastrointestinal diseases containing an extract of Cucumis melo as an effective ingredient.
  • the present invention provides a veterinary composition for preventing or treating gastrointestinal diseases containing an extract of Cucumis melo as an effective ingredient.
  • the present invention relates to a composition containing a dried persimmon extract as an effective ingredient for preventing, improving or treating gastric diseases, wherein the administration of the dried persimmon extract significantly reduces the gastric lesion index caused by gastric mucosal damage, and reduces the histamine content that causes a lot of acid secretion and mucosal damage in a state of gastric stimulation or inflammation.
  • the composition has the effect of reducing the gene expression amount of inflammatory cytokines in the gastric mucosa and increasing the gene expression amount of proteins exhibiting an antioxidant effect in the gastric mucosa and proteins having a gastric protective function.
  • Figure 1 shows the results of confirming the degree of damage to the gastric mucosa after orally administering the extract of the present invention to an animal model in which gastric mucosal damage was induced, showing (A) a photograph of the gastric mucosa and (B) a gastric lesion index (%).
  • Con is a control group in which gastric mucosal damage was induced
  • PC is a positive control group administered 5 mg/kg of famotidine
  • Cheomha is a group administered 100 mg/kg and 200 mg/kg of the extract of the present invention. * indicates that the degree of gastric mucosal damage in the positive control group (PC) or the group administered with the extract of the present invention was statistically significantly reduced compared to the control group (Con), and p ⁇ 0.05.
  • Figure 2 shows the results of confirming the degree of damage to the gastric mucosa after orally administering the apices and stems (fruit bodies) extracts of the present invention to an animal model in which gastric mucosal damage was induced, showing (A) a photograph of the gastric mucosa and (B) a gastric lesion index.
  • Con is a control group in which gastric mucosal damage was induced
  • PC is a positive control group that was administered 5 mg/kg of famotidine
  • Body is a group that was administered 25 mg/kg and 50 mg/kg of the apices and stems (fruit bodies) extracts according to the present invention.
  • * indicates that the degree of gastric mucosal damage in the group administered 50 mg/kg of the apices and stems extracts according to the present invention was statistically significantly reduced compared to the control group (Con), and p ⁇ 0.05.
  • Figure 3 shows the results of confirming the changes in the expression levels of inflammatory cytokines (IL-6, IL-1 ⁇ ), histamine and PGE2 in the gastric mucosa after orally administering the extract of the present invention to an animal model in which gastric mucosal damage was induced.
  • IL-6, IL-1 ⁇ inflammatory cytokines
  • PGE2 inflammatory cytokines
  • Con is a control group in which gastric mucosal damage was induced
  • PC is a positive control group that was administered 5 mg/kg of famotidine
  • Cheomga is a group that was administered the extract of the present invention at doses of 100 mg/kg and 200 mg/kg.
  • ##, ### indicate that the changes in the expression levels of inflammatory cytokines (IL-6, IL-1 ⁇ ), histamine and PGE2 in the control group (Con) were statistically significantly increased or decreased compared to the normal group (Nor), and ## is p ⁇ 0.01 and ### is p ⁇ 0.001.
  • *, ** indicate that the expression levels of inflammatory cytokines (IL-6, IL-1 ⁇ ), histamine, and PGE2 in the group administered the extract of the present invention were statistically significantly decreased or increased compared to the control group. * indicates p ⁇ 0.05, and ** indicates p ⁇ 0.01.
  • Figure 4 shows the results of confirming the changes in the expression levels of inflammatory cytokines (IL-6, IL-1 ⁇ ), histamine, and PGE2 in the gastric mucosa after orally administering the fruit extract of the present invention to an animal model in which gastric mucosal damage was induced.
  • Con is a control group in which gastric mucosal damage was induced
  • PC is a positive control group that was administered 5 mg/kg of famotidine
  • Overbody is a group that was administered 25 mg/kg and 50 mg/kg of the fruit extract according to the present invention.
  • #, ##, ### indicate that the changes in the expression levels of inflammatory cytokines (IL-6, IL-1 ⁇ ), histamine, and PGE2 in the control group (Con) compared to the normal group (Nor) were statistically significantly increased or decreased, and # is p ⁇ 0.05, ## is p ⁇ 0.01, and ### is p ⁇ 0.001.
  • *, **, *** indicate that the expression levels of inflammatory cytokines (IL-6, IL-1 ⁇ ), histamine, and PGE2 in the group administered with the fruit extract of the present invention were statistically significantly decreased or increased compared to the control group. * indicates p ⁇ 0.05, ** indicates p ⁇ 0.01, and *** indicates p ⁇ 0.001.
  • Figure 5 shows the results of confirming the changes in the gene expression levels of SOD-1, SOD-2, Catalase and GSH-Px in the gastric mucosa after orally administering the extract of the present invention to an animal model in which gastric mucosal damage was induced.
  • Con is a control group in which gastric mucosal damage was induced
  • PC is a positive control group that was administered 5 mg/kg of famotidine
  • Cheomga is a group that was administered the extract of the present invention at doses of 100 mg/kg and 200 mg/kg.
  • ##, ###, #### indicate that the changes in the gene expression levels of SOD-1, SOD-2, Catalase and GSH-Px in the control group (Con) were statistically significantly decreased compared to the normal group (Nor), and ## is p ⁇ 0.01, ### is p ⁇ 0.001, and #### is p ⁇ 0.0001.
  • *, ** indicate that the gene expression levels of SOD-1, SOD-2, Catalase and GSH-Px in the group administered the extract of the present invention were statistically significantly increased compared to the control group. * indicates p ⁇ 0.05 and ** indicates p ⁇ 0.01.
  • Figure 6 shows the results of confirming the changes in the gene expression levels of SOD-1, SOD-2, Catalase and GSH-Px in the gastric mucosa after orally administering the fruit extract of the present invention to an animal model in which gastric mucosal damage was induced.
  • Con is a control group in which gastric mucosal damage was induced
  • PC is a positive control group that was administered 5 mg/kg of famotidine
  • Overbody is a group that was administered 25 mg/kg and 50 mg/kg of the fruit extract according to the present invention.
  • ##, ### indicate that the changes in the gene expression levels of SOD-1, SOD-2, Catalase and GSH-Px in the control group (Con) were statistically significantly decreased compared to the normal group (Nor), and ## is p ⁇ 0.01 and ### is p ⁇ 0.001.
  • *, ** indicate that the gene expression levels of SOD-1, SOD-2, Catalase and GSH-Px in the fruit extract administration group of the present invention were statistically significantly increased compared to the control group. * indicates p ⁇ 0.05 and ** indicates p ⁇ 0.01.
  • Figure 7 shows the results of AB-PAS (Alcian Blue-Periodic acid-Schiff) staining of gastric tissue to confirm the degree of damage to the gastric mucosa after orally administering the extract of the present invention and the fruit extract to an animal model in which gastric mucosal damage was induced.
  • AB-PAS Alcian Blue-Periodic acid-Schiff
  • the present invention relates to a health functional food composition for preventing or improving gastrointestinal diseases, containing an extract of Cucumis melo as an effective ingredient.
  • additives and extracts may be prepared by a method comprising, but not limited to, the following steps:
  • a step of extracting by adding an extraction solvent to dried fruit including peel of fruit, fruit pulp excluding peel, and fruit seeds
  • fruit stem fruit body; CM
  • step (3) A step of producing an extract by concentrating the filtered extract of step (2) under reduced pressure and drying it.
  • the extraction solvent is preferably water, a lower alcohol of C 1 to C 4 , or a mixture thereof, more preferably ethanol, and even more preferably 70% (v/v) ethanol, but is not limited thereto.
  • the extraction of the additive can utilize all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction.
  • the reduced pressure concentration in the step (3) is preferably performed using a vacuum reduced pressure concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably performed using reduced pressure drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.
  • the extract of a plum means one or more selected from the peel of a plum fruit, the pulp excluding the peel (fruit), the seed of a plum fruit, and the stem (fruit body; CM).
  • the above gastric disease may preferably be a gastric disease caused by damage to the gastric mucosa, and more preferably, it is any one selected from acute gastritis, chronic gastritis, chronic active gastritis, chronic atrophic gastritis, gastric ulcer, gastric bleeding, and gastric perforation caused by damage to the gastric mucosa, but is not limited thereto.
  • composition is preferably prepared in any one formulation selected from powder, granules, pills, tablets, capsules, candy, syrup, and beverage, but is not limited thereto.
  • the additive and extract may be added as they are or used together with other foods or food ingredients, and may be used appropriately according to a conventional method.
  • the amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). In general, when manufacturing a food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, to the raw material. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range. There is no particular limitation on the type of the food.
  • Examples of foods to which the extract may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and include all health functional foods in the conventional sense.
  • composition of the present invention When used as a health beverage, it may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages.
  • the natural carbohydrates mentioned above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclotensin, and sugar alcohols such as xylitol, sorbitol and erythritol.
  • a natural sweetener such as thaumatin and stevia extract, or a synthetic sweetener such as saccharin and aspartame can be used.
  • the proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 g of the composition of the present invention.
  • the composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc.
  • the composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These components may be used independently or in mixtures. The ratio of these additives is not particularly important, but the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.
  • the present invention relates to a pharmaceutical composition for preventing or treating gastrointestinal diseases containing an extract of Cucumis melo as an effective ingredient.
  • composition of the present invention is preferably prepared in any one formulation selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols, but is not limited thereto.
  • composition of the present invention may further contain a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-mentioned effective ingredient, and may be in various oral or parenteral dosage forms.
  • a pharmaceutically acceptable carrier such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants.
  • Solid preparations for oral administration include capsules, powders, granules, tablets, pills, etc., and such solid preparations are prepared by mixing one or more compounds with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc.
  • Liquid preparations for oral administration include suspensions, emulsions, syrups, and aerosols, and in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, flavoring agents, and preservatives.
  • Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilizers, and suppositories.
  • Non-aqueous solvents and suspending agents can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • Suppository bases can include witepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin.
  • parenteral administration it is desirable to select external skin application or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine epidural, or intracerebrovascular injection methods.
  • the pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount.
  • the "pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the level of the effective amount can be determined according to the type and severity of the patient's disease, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the excretion rate, the treatment period, the concurrently used drugs, and other factors well known in the medical field.
  • the composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects by considering all of the above factors, and this can be easily determined by those skilled in the art.
  • the dosage of the composition of the present invention varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity, and the daily dosage is 0.01 to 2,000 mg/kg based on the amount of the additive and extract, preferably 30 to 500 mg/kg, and more preferably 50 to 300 mg/kg, and can be administered 1 to 6 times a day.
  • the composition of the present invention can be used alone or in combination with methods using surgery, radiotherapy, hormone therapy, chemotherapy, and biological response modifiers.
  • the present invention relates to a feed additive for preventing or improving gastrointestinal diseases containing an extract of Cucumis melo as an effective ingredient.
  • the feed additive of the present invention corresponds to supplementary feed under the Feed Management Act.
  • the term 'feed' in the present invention may mean any natural or artificial diet, meal, etc., or a component of the meal, which is suitable for animals to eat, ingest, and digest.
  • the type of the feed is not particularly limited, and feed commonly used in the relevant technical field may be used.
  • Non-limiting examples of the feed include plant feeds such as grains, roots, food processing by-products, algae, fibers, pharmaceutical by-products, fats, starches, meal, or grain by-products; animal feeds such as proteins, inorganic substances, fats, minerals, fats, single-cell proteins, zooplankton, or food. These may be used alone or in combination of two or more.
  • the present invention relates to a veterinary composition for preventing or treating gastrointestinal diseases containing an extract of Cucumis melo as an effective ingredient.
  • the veterinary composition of the present invention may further comprise suitable excipients and diluents according to conventional methods.
  • Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxy benzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.
  • the veterinary composition according to the present invention may further include fillers, anticoagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, etc., and the veterinary composition according to the present invention may be formulated using a method well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to an animal, and the formulation may be in the form of a powder, granule, tablet, capsule, suspension, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, suppository, sterile injectable solution, sterile external preparation, etc.
  • the effective amount of the veterinary composition according to the present invention may be appropriately selected depending on the individual animal.
  • test animals were 7-week-old male ICR mice, which were randomly divided into groups of 5 each after acclimation for 7 days. 100 mg/kg and 200 mg/kg of the extract and the positive control group [5 mg/kg of famotidine] were administered once a day for 5 times. Each test substance and control drug were administered orally, and 50% (v/v) ethanol was administered orally 1 hour after administration for 5 days. On the 5th day, 50% (v/v) ethanol was administered, and 1 hour after anesthesia with avertin, the stomach was removed, and the gastric mucosa was photographed. The area of the damaged area was analyzed using Image J software (NIH, Bethesda, MD).
  • Gastric lesion index [gastric lesion area/total gastric area] ⁇ 100
  • test animals were 7-week-old male ICR mice, which were randomly divided into groups of 5 each after acclimation for 7 days. 25 mg/kg and 50 mg/kg of the fruit extract and the positive control group (5 mg/kg of famotidine) were administered once a day for 5 times. Each test substance and control drug were administered orally, and 50% (v/v) ethanol was administered orally 1 hour after administration for 5 days. On the 5th day, 50% (v/v) ethanol was administered, and 1 hour after anesthesia with avertin, the stomach was removed, and the gastric mucosa was photographed. The area of the damaged area was analyzed using Image J software (NIH, Bethesda, MD).
  • Gastric lesion index [gastric lesion area/total gastric area] ⁇ 100
  • IL-6 IL-6
  • IL-1 ⁇ inflammatory cytokines
  • histamine a factor related to gastric juice secretion
  • PGE2 a gastric mucosal protective factor
  • the content of PGE2 which plays a role in protecting the gastric mucosa by increasing mucus and blood flow as a cytoprotective substance, decreased in the con group, but increased by the administration of the dried persimmon extract and the positive control group, confirming the effect of reducing gastric mucosal damage and protecting the mucosa (Figs. 3 and 4).
  • AB-PAS Alcian Blue-Periodic acid-Schiff staining is a method used to stain mucin, glycoprotein, or polysaccharide that have a protective function in the gastric mucosa within the gastric tissue, and is the most commonly used method for detecting polysaccharides. AB-PAS staining was performed on gastric tissue to determine the amount and distribution of mucin in the gastric mucosa.
  • the mucin layer that covers the gastric mucosa and acts as a protective layer was completely damaged by alcohol administration, and the thickness of the mucosa decreased due to a decrease in gastric mucosal epithelial cells.
  • the mucosal layer was protected by administration of the extracts of the citrus fruits and the fruit body, and the thickness of the mucosa and the damage to the mucin layer were improved (Fig. 7).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pour la prévention, l'amélioration ou le traitement de maladies gastro-intestinales, comprenant un extrait de Cucumis melo L. en tant que principe actif, l'administration de l'extrait de Cucumis melo L. réduisant considérablement un indice de lésion gastrique dû à une lésion de la muqueuse gastrique, réduisant la teneur en histamine, qui dans des états inflammatoires ou d'irritation gastrique entraîne une sécrétion d'acide élevée et des lésions de la muqueuse, diminuant l'expression génique de cytokines inflammatoires dans la muqueuse gastrique, et augmentant également l'expression génique de protéines avec des effets antioxydants et des protéines ayant des fonctions gastro-protectrices dans la muqueuse gastrique, et par conséquent la présente invention peut être utile en tant que médicament, aliment fonctionnel de santé ou additif alimentaire pour des maladies gastro-intestinales provoquées par une lésion de la muqueuse gastrique.
PCT/KR2024/002956 2023-03-10 2024-03-07 Composition pour la prévention, l'amélioration ou le traitement de maladies gastro-intestinales, comprenant un extrait de cucumis melo l. en tant que principe actif Pending WO2024191115A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2023-0031641 2023-03-10
KR20230031641 2023-03-10
KR1020240029392A KR20240138984A (ko) 2023-03-10 2024-02-29 첨과 추출물을 유효성분으로 함유하는 위장질환의 예방, 개선 또는 치료용 조성물
KR10-2024-0029392 2024-02-29

Publications (1)

Publication Number Publication Date
WO2024191115A1 true WO2024191115A1 (fr) 2024-09-19

Family

ID=92756164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2024/002956 Pending WO2024191115A1 (fr) 2023-03-10 2024-03-07 Composition pour la prévention, l'amélioration ou le traitement de maladies gastro-intestinales, comprenant un extrait de cucumis melo l. en tant que principe actif

Country Status (1)

Country Link
WO (1) WO2024191115A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003002840A (ja) * 2001-03-20 2003-01-08 Bio-Obtention Sc 脂肪性物質を基材とする脂溶性剤中にコートおよび／またはマイクロカプセル化されたＣｕｃｕｍｉｓｍｅｌｏ抽出物
WO2008009212A1 (fr) * 2006-07-10 2008-01-24 Botanic Century (Beijing) Co., Ltd Extrait normalisé et utilisation de ce dernier dans la fabrication d'un médicament
KR20180068274A (ko) * 2016-12-13 2018-06-21 (주)씨엘팜 씀바귀 및 멜론 혼합 추출물을 포함하는 항염증성 및 염증성 신경퇴행성 질환 예방 또는 치료용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003002840A (ja) * 2001-03-20 2003-01-08 Bio-Obtention Sc 脂肪性物質を基材とする脂溶性剤中にコートおよび／またはマイクロカプセル化されたＣｕｃｕｍｉｓｍｅｌｏ抽出物
WO2008009212A1 (fr) * 2006-07-10 2008-01-24 Botanic Century (Beijing) Co., Ltd Extrait normalisé et utilisation de ce dernier dans la fabrication d'un médicament
KR20180068274A (ko) * 2016-12-13 2018-06-21 (주)씨엘팜 씀바귀 및 멜론 혼합 추출물을 포함하는 항염증성 및 염증성 신경퇴행성 질환 예방 또는 치료용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MALLEK‐AYADI SANA, BAHLOUL NEILA, BAKLOUTI SEMIA, KECHAOU NABIL: "Bioactive compounds from Cucumis melo L. fruits as potential nutraceutical food ingredients and juice processing using membrane technology", FOOD SCIENCE & NUTRITION, vol. 10, no. 9, 1 September 2022 (2022-09-01), pages 2922 - 2934, XP093210485, ISSN: 2048-7177, DOI: 10.1002/fsn3.2888 *
SRIVASTAVA ARVIND KUMAR, MUKERJEE ALOK, RAMTEKE P. W., PANDEY HIMANSHU, MISHRA SHANTI BHUSHAN: "Antiulcer Potential of <I>Cucumis melo</I> Var. Momordica (Roxb.), Duthie & Fuller Fruits in Experimental Animal", JOURNAL OF PHARMACEUTICAL RESEARCH, vol. 16, no. 3, pages 218, XP093210482, ISSN: 0973-7200, DOI: 10.18579/jpcrkc/2017/16/3/118762 *

Similar Documents

Publication Publication Date Title
RU2500416C2 (ru) Композиции для предотвращения или облегчения желудочно-кишечных заболеваний
US20240082337A1 (en) Composition for preventing or treating gastritis or peptic ulcer
WO2017176082A1 (fr) Composition contenant un extrait d&#39;alpinia oxyphylla comme principe actif destinée à prévenir, soulager ou traiter l&#39;hyperuricémie ou un trouble métabolique lié à l&#39;hyperuricémie
WO2016167444A1 (fr) Composition pharmaceutique destinée à prévenir ou à traiter l&#39;obésité ou des maladies métaboliques lipidiques, contenant un extrait d&#39;atractylodis macrocephalae rhizoma
KR20230149562A (ko) 조협 추출물을 유효성분으로 포함하는 알러지성 호흡기 질환의 예방, 개선 또는 치료용 조성물
WO2024191115A1 (fr) Composition pour la prévention, l&#39;amélioration ou le traitement de maladies gastro-intestinales, comprenant un extrait de cucumis melo l. en tant que principe actif
WO2019083264A1 (fr) Composition pour prévenir, soulager ou traiter des maladies du foie, contenant un produit fermenté d&#39;extrait de germe de ginseng vieilli en tant que substance active
KR20240138984A (ko) 첨과 추출물을 유효성분으로 함유하는 위장질환의 예방, 개선 또는 치료용 조성물
WO2014133286A1 (fr) Composition contenant des extraits d&#39;artemisia iwayomogi et de curcuma longa en tant que principes actifs pour la prévention, l&#39;inhibition ou le traitement de maladies se rapportant à l&#39;obésité
WO2022124803A1 (fr) Composition destinée à la prévention, au soulagement ou au traitement de maladies allergiques, comprenant un extrait de spatholobus suberectus en tant que principe actif
WO2018008973A1 (fr) Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique
KR102894064B1 (ko) It104489, it221621 및 it320916 품종의 수수 추출물을 유효성분으로 함유하는 위암의 예방, 개선 또는 치료용 조성물
KR102894756B1 (ko) 절패모 추출물을 유효성분으로 포함하는 면역증진 및 염증성 장질환의 예방, 개선 또는 치료용 조성물
KR20240138985A (ko) 칠해목 추출물을 유효성분으로 함유하는 위장질환의 예방, 개선 또는 치료용 조성물
WO2021002547A1 (fr) Composition destinée à prévenir, atténuer ou traiter un syndrome d&#39;andropause, comprenant un extrait de scutellaria barbata en tant que principe actif
KR102763559B1 (ko) 금전초 추출물을 유효성분으로 포함하는 장질환의 예방, 개선 또는 치료용 조성물
WO2021246703A1 (fr) Composition anti-obésité
WO2020122373A1 (fr) Composition comprenant un extrait de glycyrrhiza uralensis en tant que principe actif pour la prévention, l&#39;atténuation ou le traitement du syndrome d&#39;hypogonadisme d&#39;apparition tardive
KR102805986B1 (ko) 구맥 추출물을 유효성분으로 포함하는 염증성 장질환의 예방, 개선 또는 치료용 조성물
WO2023224305A1 (fr) Composition destinée à prévenir, atténuer ou traiter l&#39;arthrite et la douleur articulaire, comprenant comme principe actif un extrait de lysimachia mauritiana
KR102883854B1 (ko) 조밥나물 추출물을 유효성분으로 함유하는 관절염 및 관절통증의 예방, 개선 또는 치료용 조성물
WO2024117770A1 (fr) Composition comprenant un extrait de riz coloré en tant que principe actif pour améliorer l&#39;immunité
KR20250035487A (ko) 조팝나무 추출물을 유효성분으로 함유하는 염증성 장질환의 예방, 개선 또는 치료용 조성물
KR102693539B1 (ko) 어수리 추출물을 포함하는 골다공증 예방, 개선 또는 치료용 조성물
WO2025234773A1 (fr) Composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive, contenant un extrait de galium odoratum en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24771115

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE